Treats Major Depressive Disorder (MDD). ANDA 219985, held by Aurobindo Pharma Ltd. Citalopram Hydrobromide.
As of Nov 15, 2026, ANDA 219985 (Citalopram Hydrobromide), held by Aurobindo Pharma Ltd, was first approved by FDA on Mar 13, 2026, with 0 approved supplements and 0 published complete response letters.
Citalopram capsules are indicated for the treatment of Major Depressive Disorder (MDD) in adults. Citalopram capsules is a selective serotonin reuptake inhibitor (SSRI) indicated for treatment of Major Depressive Disorder (MDD) in adults.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 13, 2026 | Original application | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Citalopram HydrobromideEQ 30MG BASE · capsule;oral | Citalopram Hydrobromide | Rx |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
